Drug Type: Protein Biologic
Conditions: ALS, GVHD
Mechanism Type: Immunomodulation
Mechanism: The strategy aims to slow progression of ALS by reducing neuroinflammation.
U.S. Status for ALS: Phase II
 MIROCALS: Modifying Immune Response and OutComes in ALS. ClinicalTrials.gov, 11 Jan 2019. Accessed 25 Jan 2019 from https://clinicaltrials.gov/ct2/show/NCT03039673.
 Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. Sheean, RK et al. JAMA Neurol. 2018 Jun 1;75(6):681-689.
 Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Thonhoff, JR et al. Neurol Neuroimmunol Neuroinflamm. 2018 May 18;5(4):e465.
 Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Matsuoka, K et al. Sci Transl Med. 2013 Apr 3;5(179):179ra43.